Program
encoberminogene rezmadenovec
Also written as “XC001” and “AdVEGFXC1”.
Its studies are mostly in Coronary Artery Disease · Angina Pectoris, led by XyloCor Therapeutics.
Furthest: phase 2, since Oct 4, 20193 company-led studies, 2 open or runningNext primary completion: Dec 30, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| XyloCor Therapeutics | 32 open or running | phase 2since Oct 4, 2019 | Oct 4, 2019 | Dec 30, 2026phase 2 · NCT07118449 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 4, 2019First study: phase 2 study in Coronary Artery DiseaseFirst studyNCT04125732 · 41 enrolled · United States
- Jun 24, 2025Phase 2 study in Angina PectorisNCT07048808 · 106 planned · United States
- Jul 17, 2025Phase 2 study in Coronary Artery DiseaseNCT07118449 · 116 planned · United States
Ahead
- Dec 30, 2026Primary completion: phase 2 study in Coronary Artery DiseaseNCT07118449
- Jun 30, 2027Primary completion: phase 2 study in Angina PectorisNCT07048808
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07118449Coronary Artery Disease · United States | 2 | Not yet recruiting | Dec 30, 2026 | 116 |
| NCT07048808Angina Pectoris · United States | 2 | Recruiting | Jun 30, 2027 | 106 |
| NCT04125732Coronary Artery Disease · United States | 2 | Completed | Jan 31, 2023 | 41 |
How it is read
Names in the registry
- “XC001”, 2 entries
- “AdVEGFXC1”, 1 entry
Conditions, from the studies’ own filings
- Coronary Artery Disease, 2 studies
- Angina Pectoris, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.